Phosphate retention and, later, hyperphosphatemia are key contributors to chronic kidney
disease (CKD)–mineral and bone disorder (MBD). Phosphate homeostatic mechanisms …

Bone and mineral metabolism becomes dysregulated with progression of chronic kidney
disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive …

Chronic kidney disease mineral bone disorder (CKD-MBD) is a common co-morbidity in
patients with CKD. Characterized by laboratory abnormalities, bone abnormality, and …

Hyperphosphatemia is a nearly universal complication of end-stage renal disease that is
widely recognized as one of the most important and most challenging clinical targets to meet …

Controlling serum phosphorus levels continues to be a challenge in patients with chronic
renal disease. Hyperphosphatemia is implicated in the development and worsening of …

Hyperphosphatemia is a predictable consequence of chronic renal failure and is present in
most patients on dialysis. Traditionally, the risk associated with elevated serum phosphorus …

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance
hemodialysis: Results of the CARE study. Most patients with end-stage renal disease …

The pathogenesis and management of chronic kidney disease-mineral bone disorders
(CKD-MBD) has experienced major changes, but the control of serum phosphorus at all …

Hyperphosphatemia is a common complication in patients with chronic kidney disease
(CKD), particularly in those requiring renal replacement therapy. The importance of …

Phosphate metabolism is crucial in the pathophysiology of secondary hyperparathyroidism
and vascular calcification. High phosphate levels have been consistently associated with …